title: [Developments in the medical treatment of overactive bladder].
abstract: Overactive Bladder (OAB) is a common problem among men and women. Antimuscarinic drugs are a reference treatment for OAB and act by blocking the muscarinic receptors (M2 and M3 subtypes) in the bladder. Adherence to antimuscarinic treatment is usually low, due to the perceived lack of efficacy and adverse effects. Therefore, new treatments with different mechanisms of action and a more acceptable tolerability profile are needed, and that improve the symptoms of OAB. Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB.
authors.affiliation: Centro de Salud José María Álvarez , Don Benito, Badajoz, España; Miembro del Grupo de Trabajo de Nefrourología de SEMERGEN. Electronic address: a.alcantara.montero@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Alcántara Montero
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron
keywords: Agonistas beta-3 adrenérgicos; Beta 3 adreno-receptor agonists; Mirabegron; Mirabegrón; Overactive bladder; Vejiga hiperactiva